![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MHRA Advises of Serious Risks for Paclitaxel-Coated Devices
MHRA Advises of Serious Risks for Paclitaxel-Coated Devices
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has warned that paclitaxel drug-coated balloons or drug-eluting stents have mortality risks that generally outweigh their benefits for routinely treating patients with widening of the arteries.
However, using the devices in patients with critical-limb ischemia remains an option in selected cases, where the benefits may outweigh the risks, the agency said.
Concerns about the use of paclitaxel-coated balloons surfaced following a December 2018 study that warned against treating patients with peripheral arterial disease, a build-up of deposits in the arteries that restrict blood supply to leg muscles.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct